Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Interferon for chronic hepatitis C in patients cured of malignancy

  • 15 Accesses

  • 14 Citations


Six patients with chronic hepatitis C who were cured of malignancy were treated with recombinant interferon-alpha at the dose of 4 MU/m2 for 12 months; the post-treatment follow up period was 12 months. Therapy was stopped within 6 months in three patients because of persistently abnormal alanine aminotransferase levels. In the remaining three patients, a complete normalization of alanine amnotransferase levels was obtained during treatment but it was not maintained after the end of interferon therapy. In addition, no patient cleared hepatitis C virus ribonucleic acid in serum. These results suggest that recombinant interferon is not effective in patients with chronic hepatitis C who were cured of a previous malignancy.

This is a preview of subscription content, log in to check access.



alanine aminotransferase

Anti-HCV :

hepatitis C virus antibodies


hepatitis B virus


hepatitis C virus


recombinant interferonalpha


recombinant immunoblotting assay second generation


  1. 1.

    Camps J, Castilla A, Ruiz J, Civeira MP, Prieto J (1993) Randomized trial of lymphoblastoid alpha-interferon in chronic hepatitis C. J Hepatol 17:390–396

  2. 2.

    Chemello L, Diodati G, Bonetti P, Pontisso P, Alberti A, TVVH group (1993) Treatment of chronic hepatitis C with different regimes of interferonalpha-2a (IFN-). Proceeding of the International Symposium on Viral Hepatitis and Liver Disease (Tokyo), pp 233

  3. 3.

    Colombo M, Kuo G, Choo QL, Donato MF, Del Ninno E, Tommasini MA, Dioguardi N, Houghton M (1989) Prevalence of antibodies hepatitis C virus in italian patients with hepatocellular carcinoma. Lancet 11:1006–1008

  4. 4.

    Dienstag JL (1983) Non-A, Non-B hepatitis. 1. Recognition, epidemiology and clinical features. Gastroenterology 85:439–462

  5. 5.

    Gillon J, Hussey AJ, Howe SP, Beckett GJ, Prescott RJ (1988) Post-transfusion non-A, non-B hepatitis: significance of raised ALT and anti-HBc in blood donors. Vox Sang 54:148–153

  6. 6.

    Hoofnagle JH, Di Bisceglie AM, Shindo M (1993) Antiviral therapy of hepatitis C: present and future. J Hepatol 17 [Suppl 3]:130–136

  7. 7.

    Jara P, Bortolotti F, Diaz M, Vajro P, De la Vega A, Hierro GL, Barbera C, Camarena C, Crivellaro C, Nebbia G, Zancan L (1993) Post-transfusion and sporadic hepatitis C in childhood. Proceedings of the International Symposium on Viral Hepatitis and Liver Disease (Tokyo), pp 206

  8. 8.

    Koretz RL, Stone O, Mousa M, Gitnick GL (1985) Non-A, Non-B posttransfusion hepatitis a decade later. Gastroenterology 88:1251–1254

  9. 9.

    Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE (1989) An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244:362–364

  10. 10.

    Lau JYN, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, Neuwald PD, Wilber JC (1993) Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 341:1501–1504

  11. 11.

    Locasciulli A, Mieli Vergani G, Uderzo C, Jean G, Cattaneo M, Vergani D, Portmann B, Masera G (1983) Chronic liver disease in children with leukemia in long-term remission. Cancer 52:1080–1087

  12. 12.

    Okamoto H, Okada S, Sugiyama Y, Tanaka T, Sugai Y, Akahane Y, Machida A, Mishiro S, Yoshizawa H, Miyakawa Y (1990) Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from 5′ noncoding region. Jpn J Exp Med 60(4):215–222

  13. 13.

    Rossetti F, Cesaro S, Pizzochero P, Cadrobbi P, Guido M, Zanesco L (1992) Chronic hepatitis B surface antigen-negative hepatitis after treatment of malignancy. J Pediatr 121:39–43

  14. 14.

    Ruiz-Moreno M, Rua MJ, Castillo I, Garcia Novo MD, Santos M, Navas S, Carreno V (1992) Treatment of children with chronic hepatitis C virus with recombinant Interferon alpha: a pilot study. Hepatology 16:882–885

  15. 15.

    Saez-Royuela F, Porres JC, Moreno A, Castillo I, Martinez G, Galiana F, Carreno V (1991) High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a ran domized, controlled trial. Hepatology 13:327–331

  16. 16.

    Simonetti RG, Calogero C, Fiorello F, Cottone M, Rapicetta M, Marino L, Fiorentino G, Craxi' A, Ciccaglione A, Giusepetti R, Stroffolini T, Pagliaro L (1992) Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. Ann Intern Med 116:97–102

  17. 17.

    Yuki N, Hayashi N, Hagiwara H, Takeara T (1993) Changes in antibodies to specific hepatitis C virus antigens with interferon-alpha therapy: analysis by recombinant immunoblot assay. Am J Gastroenterol 88:914–918

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cesaro, S., Rossetti, F., Zanesco, L. et al. Interferon for chronic hepatitis C in patients cured of malignancy. Eur J Pediatr 153, 659–662 (1994). https://doi.org/10.1007/BF02190687

Download citation

Key words

  • Chronic hepatitis
  • Hepatitis C virus
  • Childhood malignancy
  • Recombinant interferon-alpha